SLU-PP-915 Research Evidence
The SLU-PP-915 evidence base: trials, journals, and what the data does not yet show.
First Oral Compound in This Class to Work
Billon et al. (2025, J Pharmacol Exp Ther) reported dose-dependent exercise-capacity gains in mice that were retained when the compound was dosed orally (adjusted for exposure) — the first orally active compound in the SLU-PP series to show this. An earlier 2023 discovery paper (Xu et al., Eur J Med Chem) found a single injected dose raised exercise-response genes, and a 6-day course enhanced endurance.
Regulatory and Legal Status
SLU-PP-915 is not FDA-approved and has never been studied in humans as of 2026 — like its predecessor, every claim rests on mouse data. It is sold exclusively as a research-grade compound (RUO). Researchers and users should verify the legal status of SLU-PP-915 in their jurisdiction prior to purchase or use.
Trials and reviews
- Billon oral ERR agonistJ Pharmacol Exp Ther2025
Dose-dependent exercise-capacity gains in mice, retained orally
- Hampton discovery (compound 10s)Eur J Med Chem2023
Raised exercise-response genes after a single dose; 6-day course enhanced endurance
References
- SLU-PP-915 orally-active ERR agonist exercise study · Billon C, et al. · 2025